| UHC Commercial Medical & Drug | Cognitive Rehabilitation and Coma Stimulation – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Denosumab – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | FDA Cleared or Approved Companion Diagnostic Testing – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Habilitation and Rehabilitation Therapy (Occupational, Physical, and Speech) – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Home Health, Skilled, and Custodial Care Services – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Natalizumab (Tyruko® & Tysabri®) – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Office-Based Procedures – Site of Service – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Panniculectomy Surgery – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Provider Administered Drugs – Preferred Products – Commercial Medical Benefit Drug Policy | 2026-07-01 |